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Alzheimer pathogenesis involves mitochondrial dysfunction, which is closely related to amyloid-β (Aβ) generation, abnormal tau
phosphorylation,oxidativestress,andapoptosis.Alterationsinmembranalcomponents,includingcholesterolandfattyacids,their
characteristics, disposition, and distribution along the membranes, have been studied as evidence of cell membrane alterations
in AD brain. The majority of these studies have been focused on the cytoplasmic membrane; meanwhile the mitochondrial
membranes have been less explored. In this work, we studied lipids and mitochondrial membranes in vivo, following intracerebral
injection of ﬁbrillar amyloid-β (Aβ). The purpose was to determine how Aβ may be responsible for beginning of a vicious
cycle where oxidative stress and alterations in cholesterol, lipids and fatty acids, feed back on each other to cause mitochondrial
dysfunction. We observed changes in mitochondrial membrane lipids, and fatty acids, following intracerebral injection of ﬁbrillar
Aβ in aged Wistar rats. Melatonin, a well-known antioxidant and neuroimmunomodulator indoleamine, reversed some of
these alterations and protected mitochondrial membranes from obvious damage. Additionally, melatonin increased the levels of
linolenic and n-3 eicosapentaenoic acid, in the same site where amyloidβ was injected, favoring an endogenous anti-inﬂammatory
pathway.
1.Introduction
We hypothesized that due to its amphipathic nature [1],
its physicochemical functions [2] and aided by the induced
oxidative stress [3, 4], Aβ paves its own pathway from the
extracellular space to the mitochondria where it disrupts
membrane ﬂuidity and causes energetic dysfunction. This
mechanism of membrane permeabilization induced by Aβ
and its own internalization might be the major cause of
mitochondrial dysfunction.
Following injection of Aβ1−42 into the hippocampus of
healthyWistar6-month-oldrats,wereporteddepositsofthis
peptide fragment forming plaques in the extracellular space.
Thereafter Aβ was observed in cytoplasmic membranes,
especially those of axons, where it accumulated in one or
two poles of the axons giving the appearance of onion bulbs,
as observed in demyelinating pathologies. Demyelination
is also a feature of Alzheimer’s disease (AD) [5, 6]. It is
noteworthy that the animals used in the experiments had no
other condition or genetic predisposition to form plaques
or other AD features. Aβ peptide then appeared in the
cytoplasm, and ﬁnally in mitochondrial membranes, where
its presence was associated with mitochondrial dysfunction.
ThequestionremainingiswhatalterationsAβproduceinthe2 International Journal of Alzheimer’s Disease
lipid composition of mitochondrial membranes, particularly
in those fatty acids and phospholipids previously related to
the Aβ pathogeny. Moreover, if Aβ-induced oxidative stress
plays a key role in damaging lipids in cell membranes, what
is the potential role of the antioxidant melatonin when this
process aﬀects mitochondrial membranes?
Lipid and fatty acid changes have been studied primarily
inplasmamembranesorinsynaptosomespreparedfromAD
postmortem brains; those changes have been associated with
aging, Aβ deposits, dementia, and even with mild cognitive
impairment. Other results have been obtained using puriﬁed
synaptosomal plasma membranes from transgenic mouse
brain. To our knowledge, no studies have focused on mito-
chondrial membranes in response to in vivo extracellular
deposits of ﬁbrillar Aβ. This approach has relevance to the
aforementioned hypothesis and our previous results.
Thelipidsensingandlipid-regulatedproteolysisisawell-
characterized phenomenon. This involves the processing of
the sterol regulatory element binding proteins (SREBPs),
as the best known example [7]. Likewise, saturated fatty
acids are related both to amyloidogenesis and to tau
hyperphosphorylation. Palmitic acid (PA) is related to the
β-site amyloid precursor protein (APP) cleaving enzyme
(BACE1)upregulationandamyloidogenicprocessingofAPP
in primary rat cortical neurons [8]. Also, cortical neurons
growing in conditioned media from astrocytes treated with
palmitic acid and the unsaturated oleic acid expressed
hyperphosphorylation of the tau protein. This was later
found to be an oxidative-related phenomenon since the
addition of the antioxidant N-acetyl cysteine reduced hyper-
phosphorylation of tau [9]. Changes or reaccommodations
offattyacidswithinthelipidicstructuresarecontinuous,and
this may represent oxidative stress-induced remodeling [10].
However, an AD-speciﬁc or an Aβ-induced speciﬁc change
does not exist. Nonetheless, it is also known that unsaturated
fatty acids, speciﬁcally oleic and linoleic acids, may stimulate
presenilin-1 levels and γ-secretase activity, which participate
in the generation of Aβ [11].
The relationship between oxidative stress, peroxidation
of membrane lipids, and neurodegeneration has been pri-
marily explored in postmortem studies, where a signiﬁcant
decline in polyunsaturated fatty acids (PUFAs), especially
arachidonic and docosahexenoic acids, has been found [12].
These changes are directly related to the augmentation in 4-
hydroxynonenal, a toxic by-product of the peroxidation of
membrane PUFAs, especially arachidonic acid (AA) [13]. In
fact, Aβ may induce the phospholipase A2, responsible for
AA release from cytoplasmic membranes [14]. The observed
drop in docosahexaenoic acid (DHA), on the other hand,
is correlated with the dietary intake of DHA which may
reduce the amyloid burden [15] by stimulating the non-
amyloidogenic processing of APP [16]. Fatty acids modulate
the production and activity of a variety of neurotransmitters
and the alterations of fatty acids in the diet of rodents have
been demonstrated to result in changes in the ability of the
animals to learn or retain new information [17, 18]. The
ratio between unsaturated and saturated FA (U/S) expresses
the degree of unsaturation being linked to less membrane
ﬂuidity as an adaptative phenomenon. Changes in the ratio
of these fatty acids have been thought to be involved in a
variety of diseases including cancer, diabetes, and neurologic
diseases. The overproduction of Aβ leads to a decline in Δ-
9 desaturase activity with an alteration in membrane fatty
acids This results in altered membrane mobility leading to a
decline in neurotransmitter activity and a decreased release
of acetylcholine [19].
It has been demonstrated that Aβ peptides interact with
anionic lipids which leads to a signiﬁcant alteration in the
properties of the bilayer itself. Phosphate groups in anionic
lipids and aliphatic aminoacids (Val-Val-Ile-Ala) at the C-
terminal end of Aβ mediate that interaction while oxidative
stress induces a signiﬁcant rise in anionic phosphatidylserine
(Ptd-Ser). Membrane disruption induced by Aβ-peptide is
mediated through perturbations of the lipid order caused by
interaction of peptides with head groups and/or formation
of micelles [20]. Reciprocally, when incubated with Ptd-
Ser, Aβ undergoes transformation from a random coil to
a β-structure [21]. Furthermore, there seems to be a cell
selective neurotoxicity due to Aβ determined by surface Ptd-
Ser, apart from the levels of ATP [22]; this also relates to
our hypothesis. Thus, the capacity of cells to bind Aβ seems
to be associated with cells with expressed measurable Ptd-
Ser on the membrane surface, and this feature is correlated
with apoptotic signaling. It should be noted that Ptd-Ser is
normally found on the inner face of the surface membrane
of healthy cells. In the early stage of apoptosis, however, or
underspeciﬁcstimulation,suchasCa2+ inﬂux,ahallmarkin
the mitochondrial pathogenic mechanisms possibly involved
in AD [23, 24], Ptd-Ser can translocate to the outer leaﬂets
of the plasma membrane and be exposed to the extracellular
space. Thus, Ptd-Ser becomes a surface receptor site for Aβ
binding, in such a manner that annexin or apolipoprotein
E2, proteins with the ability to interact with Ptd-Ser, may
protect neurons from Aβ neurotoxicity [25]. Since Ptd-Ser
is an anionic phospholipid, it may produce an acidic local
environment, which is optimal for aggregation of the Aβ
peptide [26].
Phosphatidylcholine (PtdChol) is a major constituent of
cell membranes, commonly found in the outer leaﬂet, and it
isaparticulartargetforAβ.Forexample,evaluatedinzwitte-
rionic bilayers based on PtdChol membranes, Aβ associates
with lipid heads, and when fused into a zwitterionic planar
bilayer, it is rapidly transformed from helical- to β-structure
and exhibits a channel-like behavior [27]. In this manner, Aβ
disturbs intracellular calcium homeostasis because it renders
lipid bilayers permeable to ions.
Changes in packing and orientation of phospholipids
in membranes is a phenomenon promoted by cholesterol,
which modulates the membrane binding of amyloidogenic
proteins [28, 29]. It has been documented that cholesterol
increases the binding of Aβ to lipid membranes [30,
31]. The concentration of cholesterol in the membranes
has been related to the extent and depth of insertion
of Aβ into the membrane [32] .H o w e v e r ,ac o m p u t a -
tional study using PtdChol and PtdChol/cholesterol bilay-
ers, which mimic the cholesterol depleted and enriched
lipid domains of neuronal membranes, revealed a pro-
tective role of cholesterol in preventing both Aβ-inducedInternational Journal of Alzheimer’s Disease 3
membrane disruption and membrane surface-induced β-
sheet formation [33]. Nonetheless, by electron paramagnetic
resonance spectroscopy, it has been demonstrated how,
driven by hydrophobic interactions, Aβ is inserted into
bilayers, between the outer part of the hydrophobic core and
the external hydrophilic layer. This causes displacement of
cholesterol towards the more external part of the membrane
where the crowding of cholesterol in turn causes membrane
rigidity in this region of the bilayer [34]. This membrane
rigidity has been demonstrated in mitochondria obtained
from postmortem AD brain [35]; importantly, alterations
in mitochondrial membrane ﬂuidity are primarily related
to lipid peroxidation [36], which, again, emphasizes the
importance of oxidative stress.
Since oxidative stress is a major event in AD progression
and is especially related to membrane dysfunction, mito-
chondrial failure, and apoptosis, the antioxidant melatonin
has proven useful in delaying the progression of damage
in AD [24]. We have demonstrated in in vivo experiments
after the injection of Aβ directly into the hippocampus that
orally administered melatonin is more eﬀective in reducing
oxidative stress than are vitamins C and E [4]. The eﬀect
of melatonin has been shown to be especially protective
for PUFAs during nonenzymatic lipid peroxidation [37], as
observed in transgenic mouse model of AD [38]. Melatonin
alsomaypreservearachidonicanddocosapentaenoicacidsas
observedduringascorbate-Fe++ peroxidationinrattesticular
microsomes and mitochondria [39].
The current work is based in those fatty acids or lipids
previously reported to be involved in Aβ-lipid interactions
and the protective eﬀect of melatonin on Aβ-induced mem-
brane disruption; this latter process is mediated through
perturbations of the lipid order caused by an interaction
of peptides with head groups and/or formation of micelles
[20]. Our results correspond exclusively at the region of the
hippocampus where the Aβ was injected.
2.MaterialsandMethods
2.1. Animals and Experimental Design. Surgical and animal
care procedures were performed with strict adherence to the
guide for the Care and Use of Laboratory Animals (National
Institutes of Health, publication number 86–23, Bethesda,
MD, USA). All protocols and procedures were approved
by the institution’s Animal Care and Use Committee. Male
Wistar rats (250–280 grams; 3-month-old) were housed in
pairs in a colony room on a 12:12 dark/light cycle with lights
oﬀ at 20:00h; food and water were provided ad libitum. The
rats were divided (n = 5) into the following groups: (1) PBS-
injected rats, (2) ﬁbrillar Aβ1−42-injected rats (fAβ), and (3)
H2O2 (200μM) intracerebrally injected rats. Two additional
groups,fAβ+MelandH2O2+Mel,wereincluded.Inthiscase,
the fAβ or H2O2-intracerebrally injected animals received
antioxidanttreatmentwithmelatonin(Sigma,St.Louis,MO,
USA) dissolved in the drinking water to yield an estimated
daily dose of 20mg/kg/day. IPBS was used as control instead
ofAβpeptidessinceevennontoxicAβderivatives,suchasthe
scrambled Aβ usually employed as control in in vivo models,
may themselves produce free radicals [40, 41]. H2O2 was
chosen as a positive control because of its close relationship
with Aβ pathogeny [42]. H2O2 is considered its principal
mediator [43] and secondary messenger of death signals
[44]. Additionally, H2O2 accumulates in mitochondria long
beforetheappearanceofAβplaquesintheextracellularspace
as evaluated in Tg2576 mice [45].
2.2. Brain Coordinates for Hippocampal Injections. Hip-
pocampal injections of Aβ1−42 (2μL at a ﬁnal concentration
of1mM)wereperformedas previouslydescribed [4,46,47].
Lyophilized synthetic Aβ1−42 (Sigma, St. Louis, MO, USA)
peptide was solubilized (10−4M) in ﬁltered PBS; it was
then allowed to incubate with continuous agitation (Teﬂon
stir bar at 800rpm) at 23◦Cf o r3 6 hi no r d e rt of o r m
ﬁbrillar aggregates. Rats, anaesthetized with chloral hydrate
(350mg/kg, i.p.), were placed in a stereotaxic instrument
for intracerebral injection over a 5min period (coordinates:
anterior-posterior = −3.8mm, medial-lateral = 2.0mm,
dorsal-ventral = 2.6mm from bregma; this corresponds to
the CA1 region as determined by the atlas of Paxinos and
Watson [48] as a guide) using 5μL Hamilton microsyringe
coupled to a 30-gauge needle through ﬂexible tubing. The
needle was left in place for 5min after the injection. The
same coordinates were used for experiments with H2O2.
36 hours after the injections, rats were deeply anesthetized
and transcardially perfused with 200mL of PBS. Those
animals used for immunohistochemical procedures were
additionally perfused with 4% paraformaldehyde. The rats
were sacriﬁced by decapitation and the brain was removed
immediately, placed in cold PBS, and a piece of tissue (164–
180mg), including the lesioned area, was taken with a punch
(diameter 10mm), at the base of the needle tract. This piece
included the hippocampus and adjacent cortical areas.
2.3. Immunoelectron Microscopy. For immunoelectron
microscopy, the hippocampal tissue samples were ﬁxed in
4% paraformaldehyde for 24 hours and immersed in 2.3M
sucrose solution for 24 hours. Thereafter, small blocks were
cut and postﬁxed in osmium tetroxide (2% in PB 0.2M)
for 45 minutes and then embedded for 48 hours in Embed
812 (Electron microscopy Sciences). Ultrathin sections of
70–90nm were cut with an ultramicrotome (Reichert Om3)
and mounted on nickel grids and then incubated for 2 hours
in 5% BSA and 0.1% ﬁsh gelatin. For the immunolabeling
experiment, the mounted sections were then incubated
for 24 hours at 4◦C with the primary polyclonal antibody
Anti-βA( A n t i - βA42, from Santa Cruz) at a dilution 1:1000,
then washed four times with PBS 0.1M and 0.1% tween-20,
and further incubated for 3 hours at room temperature
with a 6nM gold-conjugated secondary goat anti-rabbit
antibody (Jackson Immunoresearch Laboratories) at a
dilution of 1:500. After four washes with PBS, sections were
counterstained with uranyl acetate (2%) for 15 minutes and
lead citrate for 5 minutes and examined in a Zeiss EM 906
transmission electron microscope (Oberkochen, Germany).4 International Journal of Alzheimer’s Disease
2.4. In Vivo Analysis of Mitochondrial Free Radicals. Analysis
of mitochondrial free radical generation-Mitotracker red
CM-H2XRos(MolecularProbes),arosaminederivativeused
to detect mitochondrial free radicals, was diluted in DMSO
to form a 1mM stock solution. 100μL of that solution was
diluted in 5mL of physiological saline and stored sterile at
4◦C as a working solution. Applied at a dose of 0.030μg/kg,
CM-H2XRosdidnotaﬀectthefunctionalpropertiesofmito-
chondria after loading, since neither the respiratory output
nor cell viability was signiﬁcantly changed, as evaluated in
a separate study (data not shown). Two hours following the
intraperitoneal injection of CM-H2XRos, animals were per-
fused transcardially with PBS followed by 4% paraformalde-
hyde. The brain was immediately removed and immersed
in the ﬁxative for 8–10h. Following a brief washing in PBS,
brain slices were cut into 25–30μm thick sections, including
the area of interest, with the vibratome and incubated free-
ﬂoating in Mito Tracker Green (Molecular Probes, Ex/Em
490/516nm), which selectively stains mitochondria both in
live cells and in cells that have been ﬁxed. Then sections
were mounted on adhesive (Vecta Bond) coated glass slides,
with a DNA dye, 4 ,6 diamidino-2-phenylindole (DAPI),
containing mounting medium (Vectashield, Vector Labo-
ratories) in order to evaluate mitochondrial mass in cells
with nuclear counterstaining in blue (Ex/Em 359/461nm).
Themitochondrialfreeradicalswereanalyzedbymonitoring
the oxidized ﬂuorescence product (Ex/Em 554/576nm) of
CM-H2XRos under a ﬂuorescence microscope. Integrated
optical density (IOD), number of mitochondria, and its
mitochondrial area were determined by using image analysis
software (Image-Pro Plus v5.0). Results are presented here as
a CMH2XRos/MitGreen IODs quotient.
2.5. Mitochondrial Isolation. For mitochondrial isolation,
brieﬂy, brain tissue was minced and placed in prechilled
Dounce homogenizer with SHE buﬀer (0.25M sucrose,
5mM HEPES and 1mM EGTA,. PH 7.4), followed by
centrifugation at 2,500rpm for 10min, 4◦C, and recentrifu-
gation of the supernatant (8,500rpm, 10min), to obtain a
crude mitochondrial pellet. Following a 10min incubation
in ice, the pellet was resuspended again in SHE plus deli-
pidized bovine serum albumin (Sigma Chemical Company).
Albumin was eliminated by centrifugating this suspension of
mitochondria at 9,500rpm for 10min. The protein content
in the mitochondrial fraction was determined by Lowry’s
method [49].
2.6. Fluidity Changes of Mitochondrial Membranes. 1,3 dipy-
renylpropane (DPP) incorporation into membranes to form
intramolecular excimers depends mainly on medium micro-
viscosity and temperature of determination (24). Membrane
ﬂuidityisdeterminedbyestimatingtheexcimertomonomer
ﬂuorescence intensity ratio (Ie/Im) of this ﬂuorescent probe,
a quotient that reﬂects lateral mobility of membrane
phospholipids (25). Brieﬂy, mitochondria were resuspended
in Tris-HCl buﬀer (50mM, pH 8) and then fragmented
by sonication for 15 seconds before being separated by
centrifugation at 13,000rpm. The mitochondrial membrane
pellet was resuspended and proteins were measured by
Lowry’s method. 0.1mg of mitochondrial protein was mixed
in a spectroﬂuorometric cell containing Tris-HCl (20mM,
pH 7.5). DPP solution in ethanol of spectroscopic grade
was diluted (0.02mg/mL) and mixed with membranes
given a molar ratio of ﬂuorescent probe to membrane
phospholipids of 1:1400; these mixtures were incubated in
darkness for 4 hours at room temperature. Fluorescence of
DPP incorporated into membranes was measured at 24◦C
on a Perkin Elmer ﬂuorescence spectrometer, LS50B. The
ﬂuorophore was excited at 329nm and the monomer and
excimerﬂuorescenceintensitieswerereadat379and480nm,
respectively.
2.7. Chromatographic Analysis of Fatty Acids. Fatty acids
from membranes were extracted with chloroform:methanol
(2:1vol/vol) and analyzed by gas-liquid chromatography.
Brieﬂy, C17:0 heptadecanoic acid, as internal standard, was
added to 1mg of mitochondrial protein and the mixture
of methanol and chloroform, both dissolved in BHT, was
added. After centrifugation, the chloroform phase was
extracted and a second extraction was done by adding
anhydrous sodium sulphate. The extract was evaporated
under nitrogen, reacted with a mix of methanol, sulfuric
acid, and toluene at 90◦C for2hours, and thenredissolved in
hexane and a 5% saline solution. Following the extraction of
theorganicphase,thehexanewasevaporatedundernitrogen
to obtain derivatized fatty acids to be placed into the injector
of a Carlo Erba gas chromatograph with ﬂame ionization
detection; the temperature of the injector was 250◦C and the
oven temperature was maintained at 196◦C, using helium as
a carrier gas at 1.4kg/cm2.
2.8. Chromatographic Anaylsis of Phospholipids. Phospho-
lipids were extracted with a methanol/chloroform solution
mixed in a 2:1 ratio, dried in a SpeedVac, and then
redissolved in chloroform. Following a second extraction
addinganhydroussodiumsulphate,thesolutionwasﬁltrated
and then evaporated. Samples were analyzed by high-
pressure liquid chromatography. Results are provided in
relative percentage from the correspondent areas in the
chromatogram.
2.9. Chromatographic Anaylsis of Cholesterol. Membrane
lipids were extracted with chloroform:methanol (2:1vol/
vol) and analyzed by gas-liquid chromatography. Brieﬂy,
10μg of stigmasterol, asinternal standard, wasadded to 1mg
of mitochondrial protein and the mixture of methanol and
chloroform, both dissolved in BHT, was added. Extracted
lipids react for 1 hour at 60◦C with a mix of hexamethyld-
isilazane, trimethyl ﬂuorosilane, and dry pyridine to convert
free cholesterol and stigmasterol in their corresponding
trimethyl esters. The mixture was evaporated with nitrogen
and then redissolved in hexane to be injected into the Carlo
Erba gas chromatograph with ﬂame ionization detection;
the temperature of the injector was set to 275◦C, the
temperature of the detector was 260◦C, and that of the ovenInternational Journal of Alzheimer’s Disease 5
was maintained at 275◦C. Helium was used as a carrier gas at
1.5kg/cm2.
2.10. Statistical Analysis. All data are shown as means ± SE
of triplicate experiments. Statistical analysis of the data for
multiple comparisons was performed by two-way ANOVA
followed by Student’s tests. For a single comparison, the sig-
niﬁcance of any diﬀerences between means was determined
by unpaired t-tests. The criterion for signiﬁcance was P<
0.05 in all statistical evaluations.
3. Results
3.1. Aβ at the Brain Enters the Neurons and Eventually
Presents in Mitochondrial Membranes. 12, 24, 36 and 48
hours following the intracerebral injection of ﬁbrillar Aβ,
deposits of Aβ forming aggregates were reactive to Aβ
polyclonal antibody and revealed by immunohistochemistry.
Congophilic amyloid deposits remained visible up to 21
days following the intracerebral injection (data not shown).
Tissue sections of 50μm, obtained with a vibratome, were
used for immunoelectron microscopy and the Aβ positive
immunoreactions were observed in mitochondria along the
membranes and deep in the cristae. The presence of Aβ
deposits in mitochondria was accompanied by a signiﬁcant
lost of their architecture, characterized by swelling, broken
cristae, lost of membrane integrity, and vacuole formation
(Figure 1).
3.2. The Lost of the Cytoarchitecture Was Related to Free
Radical Overproduction. CM-H2XROS is a reduced, non
ﬂuorescent X-rosamine derivative, which is sequestered by
mitochondria where it is retained and oxidized. Under oxi-
dation, CM-H2XROS emits ﬂuorescence as a consequence
of the number of free radicals produced by mitochondria.
This reagent is normally used in in vitro experiments after
adding it to cells in culture. To demonstrate the eﬀects
of Aβ in vivo, we have introduced a variant by injecting
CM-H2XROS intraperitoneally 15 minutes before tissue
collections (as explained). Once the tissue was obtained,
sections of the lesioned area were immediately cut in a
vibratome and stained with Mito Tracker Green (MitGreen),
which is essentially nonﬂuorescent in aqueous solutions,
only becoming ﬂuorescent once it accumulates within the
lipid environment of the mitochondrion. Thus, the CM-
H2XROS/MitGreen IOD quotient identiﬁes the quantity of
free radicals by the mitochondria present on each ﬁeld of the
microscope. We found a signiﬁcant overproduction of free
radicals both in Aβ- and in H2O2-treated brains (P<0.05)
as compared to PBS-injected brains. Brains of animals who
had received melatonin showed signiﬁcantly lower levels of
free radicals (P<0.05) (Figure 2).
3.3. Membrane Fluidity Was Inversely Correlated to Free
Radical Overproduction. The highest value in membrane
ﬂuidity was observed in PBS-injected brains, which showed
the lowest amount of free radicals as well (Figure 3). The
highestoverproductionoffreeradicals,accordingtotheCM-
H2XROS/MitGreen IOD quotient, was observed in H2O2-
injected brains. Interestingly, even though the production
of free radicals in brains injected with fAβ was signiﬁcantly
higher than the quantity of free radicals observed in the
PBS group, the diﬀerence between membrane ﬂuidity and
free radical overproduction was less obvious, as compared
with the positive control group of H2O2. Brains of animals
treated with melatonin had signiﬁcantly reduced levels of
free radicals and the diﬀerence between these and membrane
ﬂuidity was again obvious (Figure 3).
3.4.TheUnsaturated/SaturatedRatio,SigniﬁcantlyAﬀectedby
Aβ,I sR e s t o r e db yM e l a t o n i n .Aβ increased palmitic (16:0)
and estearic (18:0) saturated fatty acids, 39 and 37% (P<
0.05), correspondingly. Additionally, Aβ reduced linoleic
acid (18:2) at less than 35% the observed value in the
PBS-injected brains (P<0.05) and decreased linolenic
acid (18:3) value 80% below the observed value in the
PBS-injected brains. Additionally, Aβ signiﬁcantly increased
the polyunsaturated arachidonic acid (20:4) (P<0.05,
from 29.4 ± 2t o5 1± 2.5). Thus, the elevated increase in
saturated plus the severe decrement in linoleic and linolenic
acids (Figure 4) was mostly responsible for an alteration in
the ratio of unsaturated to saturated fatty acids in membrane
phospholipids which is critical to normal cellular function.
The lower unsaturated to saturated ratio was observed
in fAβ-injected brains to be even lower than the positive
control group of H2O2,f A β and H2O2 being the groups of
study where the overproduction of free radicals was signif-
icant (Figure 2). With the use of melatonin, the U/S ratio
returned signiﬁcantly closer to control values (Figure 5),
which reﬂected melatonin’s role on each particular fatty acid
(Figure 4).
However, the aforementioned showed that a drastic
reduction in linolenic acid, a precursor of arachidonic acid
(20:4, n6), and in linoleic acid, a precursor of docoso-
hexanoic acid (22:6, n3), was reﬂected in the Aβ-induced
levels of AA and DHA levels (Figure 6). In the Aβ-injected
brains, arachidonic acid rose 20% in relation to the PBS-
injected control values (P<0.05), while DHA levels showed
approximately 30% increase value (P<0.05). This similar
increment in both variables allows that the relationship
between these relative values or DHA/AA ratio remains
stable in Aβ-injected brains as compared to PBS-injected
brains (Figure 6).
Except for the palmitic acid and the arachidonic acid, the
rest of the Aβ-altered fatty acids tend to return to their basal
levels, similar to PBS levels, when the animals were treated
with melatonin (fAβ+Mel group), as shown in Figures 4–
6. Another exception was the N3, 20:5, polyunsaturated
eicosapentaenoic fatty acid (EPA) which seemed to be
unaﬀected by Aβ (Figure 7). However, the EPA-to-AA ratio
showed a signiﬁcant reduction (P<0.05). Interestingly,
in Aβ-injected brains from melatonin-treated animals, EPA
valueswere60%and43%higherthanthoseobservedinPBS-
and in Aβ-injected brains. As a result, the EPA to AA ratio
was restored (Figure 7).6 International Journal of Alzheimer’s Disease
(a) (b) (c)
Figure 1: Aβ stain by immunoelectron microscopy. 36 hours after the intracerebral injection of Aβ tissues from the injected area were
obtained and subjected to immunohistochemistry by using a primary polyclonal antibody against Aβ.D e p o s i t so fA β forming deposits
in the extracellular space were revealed by conventional light microscopy (data not shown). Aβ immunoreactivity was then revealed with a
6nmgoldlabelandobservedinatransmissionelectronmicroscopewhichallowsustoidentify(a)depositsofAβ withinmyelinaxons(black
arrows) and in the vasculature (white arrows). (b) Deposits of Aβ (black arrows) penetrate the axon membranes causing demyelination and
appear in the axons. Axons look like bulb onions. (c) Aβ appears within the mitochondria ﬁnally, where it forms deposits along the cristae
(black arrows) and causes intense inﬂammation, destruction of membranes, and vacuolization (magniﬁcation at 27800x).
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Figure2:ComparedwithPBS-injectedbrains,thosebrainsinjected
with Aβ or with H2O2 had a signiﬁcant increase in free radical
levels in mitochondria, according to the CM-H2XROS/MitGreen
quotient (∗P<0.05 versus all the other groups). However, by using
melatonin a signiﬁcant decrease in mitochondrial free radicals was
observed both in Aβ- and in H2O2-injected brains.
3.5. Aβ Induced Signiﬁcant Alterations in Mitochondrial
Membrane Phospholipids. Thus, while the eﬀect of phos-
phatidyl ethanolamine (PtdEA) levels was reduced by a
third in the fAβ group (P<0.05), levels of phosphatidyl
choline (PtdCHOL) were increased 40% (P<0.05), but
the phosphatidyl serine (PtdSER) values reached 120% as
comparedtoPBS-injectedbrains(Figure 8).Onthecontrary,
brains of animals treated with melatonin showed PtdEA
levels similar to PBS-injected brains, while levels of PtdSER
were signiﬁcantly reduced with melatonin even beyond the
c o n t r o lv a l u e s( P<0.05). PtdCHOL levels were also
signiﬁcantly reduced in presence of melatonin (Figure 8).
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Figure 3: Brains of animals injected with Aβ showed a signiﬁcant
reduction in membrane ﬂuidity as compared with PBS-injected
brains, although less obvious than the observed in H2O2-injected
brains, used as a positive control, which is in concordance with the
degree of the free radicals overproduction, as shown in the previous
graphic. Membrane ﬂuidity in animals receiving melatonin was
restored at the same level than the PBS group.
3.6. Variations in Cholesterol Content Follow the Same Pattern
As Variations in Free Radicals. The lowest cholesterol values
were found in the PBS-injected brains and the highest values
were observed in the H2O2-injected brains (P<0.05).
The concentration of cholesterol in fAβ-injected brains was
signiﬁcantly higher (59.6 ± 5.7v e r s u s4 7 .6 ± 5.2μg/mg of
protein, P<0.05) than that in the control brains treated
withPBS;thisvaluewasonly66%thevalueinH2O2-injected
brains (59.6±5.7v e r s u s9 0 .24±11, data not shown). In spite
of the signiﬁcant increase in the membrane ﬂuidity observed
in fAβ+Mel brains, this change was apparently not related to
the cholesterol content since melatonin did not change the
levels of cholesterol in fAβ-injected brains (fAβ 60±6v e r s u sInternational Journal of Alzheimer’s Disease 7
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Figure 4: Aβ and H2O2 (not shown) had similar and highly signiﬁcant eﬀects on saturated fatty acids particularly on palmitic and estearic
acids whose percentages were increased 39 and 37% correspondingly. Linoleic acid was reduced to a third from the control, while linolenic
acid was reduced to less than a quart from the control value, as shown. These important eﬀects of Aβ on speciﬁc saturated and unsaturated
fatty acids aﬀected the unsaturated/saturated (U/S) balance.
fAβ+Mel61±7)(Figure 9).Thecholesterol-to-phospholipid
ratio, on the other side, which reﬂects a loss of phospholipid
and membrane rigidity, was signiﬁcantly altered by Aβ,w i t h
the inability of melatonin to return it to the level found in
PBS-injected brains (Figure 9).
4. Discussion
Lipid and fatty acid changes have been studied in plasma
membranes, especially in both postmortem AD brain and
transgenic mice. These changes have been associated with
aging, Aβ deposits, dementia, and even mild cognitive
impairment. Other experiments have been carried out in
vitro by using puriﬁed synaptosomal plasma or mito-
chondrial membranes. To our knowledge, no studies have
focused on mitochondrial membranes in response to in vivo
extracellular deposits of ﬁbrillar Aβ. In spite of its known
ability to induce oxidative stress, alterations in lipid content
of mitochondrial membranes induced by extracellular Aβ
diﬀered from those induced by H2O2.
Mitochondrial dysfunction has been related to oxidative
stress in neurodegeneration as both cause and eﬀect. At the
same time, there is increasing evidence for membrane lipid,
fatty acid, and cholesterol interactions with Aβ. These inter-
actions have signiﬁcant consequences in the pathogenesis of
Alzheimer’s disease. Our original aim was to demonstrate
that extracellular deposits of Aβ, in vivo, would be able to
induce mitochondrial failure as well as changes in mitochon-
drial lipid composition as a consequence of its ability to
induce oxidative stress. H2O2 was chosen as positive control
since endogenous hydrogen peroxide has been indicated as a
secondarymessengermediatingtheintracellulareﬀectsofAβ
extracellular deposits. Furthermore, a relationship between8 International Journal of Alzheimer’s Disease
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Figure 5: fAβ-injected brains decreased signiﬁcantly the U/S ratio,
as compared with the PBS-injected brains. However, brains of
animals taking oral melatonin showed a U/S ratio closer to the
control group.
the accumulation of Aβ monomers and oligomers and H2O2
production in the mitochondria of Tg2576 mice has been
reported. However, we found that important Aβ-induced
alterations were signiﬁcantly diﬀerent from those induced by
H2O2. AA levels, for example, were signiﬁcantly higher in
the fAβ group than those in the H2O2 group (P<0.05).
T h er a t i oU / Sw a sn o ta ﬀected by H2O2, basically due to
minimal eﬀects on or to compensations between decrements
and increments in one or another group of saturated versus
unsaturated fatty acids. Aβ, increasing saturated fatty acids
and decreasing unsaturated fatty acids, caused a persistent
and signiﬁcant decrement of the U/S ratio (Figure 5). This
ﬁnding agrees with another work where the ability of Aβ to
interfere with the Δ-9 desaturase enzyme was observed. Δ-9
desaturase introduces the ﬁrst double bond between carbon
9 and 10 of palmitoyl (16:0) or stearyl (18:0) Co A to form
palmitoleic (16:1) or oleic (18:1) acids [19].
This profound fatty acid imbalance was reﬂected in
phospholipid levels, in such a manner that H2O2 did not
aﬀect the levels of PtdEA, but Aβ reduced signiﬁcantly this
phospholipid. However, the most severe eﬀect of Aβ was
observed in PtdSER, causing a 5-fold increment, whereas
H2O2 did not aﬀect this parameter.
There seems to be a diﬀerent mechanism of damage.
While the strict oxidative damage, represented by our
positive control group H2O2, caused the highest increment
in PtdEA levels, Aβ reduced PtdEA levels and, on the
contrary, increased very signiﬁcantly the PtdSER levels and,
less important but also signiﬁcantly, the PtdCHOL levels
(Figure 10).
Thus, Aβ deleterious eﬀects were not oxidative stress
related—or at least not completely explained by oxidative
alterations—which is evident when comparing the diﬀering
eﬀects of H2O2 and Aβ on membrane lipids (P<0.05).
Fatty acid (FA) composition of phospholipids determines
biophysical (and functional) characteristics of membranes
(e.g., membrane ﬂuidity) and plays an important role in
cellular integrity and intra- and intercellular communica-
tion. We found a signiﬁcant (P<0.001) inverse correlation
(r2 =− 0.74) between mitochondrial membrane ﬂuidity and
cholesterol content. Indeed, we found that Aβ and H2O2
causedthemoresevereoxidativestress,thelowestmembrane
ﬂuidity, and the highest cholesterol content. However, in
the Aβ group the reduction of oxidative stress seemed not
to aﬀect the cholesterol increment, although Aβ had a
more severe eﬀect on fatty acids (Figures 5, 6,a n d7)a n d
phospholipid redistribution (Figure 10).
A tendency of cholesterol to aggregate into clusters at a
cholesterol/phospholipid ratio of greater than 0.3 is known
since 1972 [50], and we have found a 0.3 ± .08 cholesterol
to phospholipid ratio in fAβ-injected brains due principally
to a severe decrement in PtdEA against an increment in
cholesterol content (Figures 8 and 9). Cholesterol aggregates
in membranes are a well-known characteristic of Aβ-
induced damage [30, 51, 52]. High-cholesterol diet has been
associated with increased deposits of Aβ [53], and we have
found [54] that animals fed with a cholesterol-enriched diet
presented a signiﬁcant increase in mitochondrial structural
damage linked to severe dysfunction of this organelle. It
was noticeable that, according to our results, melatonin
could not impair this cholesterol re-arrangement but was
able to induce a signiﬁcant increment in membrane ﬂuidity
(Figure 3). This phenomenon illustrates the role of lipid
peroxidation and the reaccommodation of phospolipids,
particularly PtdSer and PtdEA, along the membranes as
determinants of membrane ﬂuidity, beyond the role of
cholesterol [55].
Aβ42 oligomers accumulate more slowly and in reduced
amountattheplasmamembranesofﬁbroblastsfromfamilial
AD(FAD)patientsenrichedincholesterol[56].Ontheother
side, it is also reported that Aβ binds lipids, but with a higher
aﬃnityforcholesterolthanPtdCHOLorsaturatedfattyacids
[51]. We may therefore speculate, according to our results,
that the cholesterol rearrangement observed in brain cells
may be a defensive response against oxidative stress, with a
secondary eﬀect, Aβ binding.
Speciﬁc alterations in fatty acids have been related to
Aβ pathogenesis. For example, unsaturated fatty acids oleic
acid, and linoleic acid, have been shown to increase the γ-
secretase activity and Aβ levels, as evaluated in PSwt-1 cells,
which contains the wild-type human presenilin 1 (PS1) and
wild-type human APP full-length cDNAs, [11]. According
to our results, Aβ decreased severely the content of linoleic
acid (6.5mol% in PBS-injected brains versus 2.12mol% in
Aβ-injected brains, P<0.05), as observed in old Wistar rat
brain, which implies that this eﬀect occurs regardless of the
ApoE phenotype.
The importance of the ApoE phenotype involves the
carrying of proteins in combination with lipids to form
lipoprotein particles with hydrophobic lipids at the core and
hydrophilic side chains made of amino acids. ApoE also aids
the transport of triglyceride, phospholipid, and cholesterol
into cells, by mediating the binding, internalization, and
catabolism of lipoprotein particles [57]. ApoE is considered
a risk factor in AD because 40–65% of AD patients have at
least one copy of the 4 alleles; although the exact mechanismInternational Journal of Alzheimer’s Disease 9
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Figure 6: Aβ and H2O2 (not shown) produced important increases in both n6 and n3 PUFA, which reﬂects the previous described changes
in free fatty acids. A similar increase in DHA and AA allowed the DHA/AA ratio to remain stable, when compared with the PBS group. It is
obvious that melatonin reduces the DHA/AA ratio, particularly at the expense of a decrease in DHA levels.
of this feature remains to be fully determined, an interaction
withamyloidinsolubleproteinaggregatesorwithAPPseems
to be involved [58, 59]. How ApoE controls brain lipids and
how this regulation may impact the clearance of Aβ or the
progression of damage are less clear [60]. In postmortem
brainsamples,nosigniﬁcantdiﬀerenceinlipidsorfattyacids
was found between AD patients classiﬁed as homozygous
for ApoE4 and those classiﬁed as heterozygous or having no
ApoE4 [10,61].Thus,ApoEgenotypeonfattyacidsandlipid
composition and/or its distribution in brain cell membranes
seem to have no signiﬁcance and would not bias our results.
Additionally, by comparing the association of human, rat,
and rabbit ApoE with Aβ, a similar lack of aﬃnity for Aβ
betweenratApoEandhumanApoE4hasbeenreported[62].
Thus, rat ApoE, the same as the AD-related ApoE4, does not
form complex with Aβ.
Anotherfattyacidwhoserelationship withAβ pathogeny
has been widely studied is AA. This N6 PUFA is an agonist of
proinﬂammatory pathways, which additionally as has been
reported increase the levels of Aβ [63]. It is known also that
Aβ oligomers trigger neuronal apoptosis by early activation
of a cPLA2-dependent pathway leading to production of
AA [14]. We found that the AA precursor linoleic acid was
reduced while AA was increased by Aβ, which supports the10 International Journal of Alzheimer’s Disease
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Figure 7: EPA was not to signiﬁcantly responsive to Aβ. However, in the presence of melatonin and contrary to the results with the other
major n3 PUFA, DHA, the relative percentage of EPA rose signiﬁcantly, which impacted the EPA/AA ratio, as shown.
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Figure 8: Aβ decreased signiﬁcantly the PtdEA levels and increased the levels of PtdCHOL and PtdSER, the latter with a 5-fold increment.
Results are expressed in relative percentage ± standard error.International Journal of Alzheimer’s Disease 11
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Figure 9: Cholesterol content in mitochondrial membranes is signiﬁcantly increased in fAβ injected brains. The H2O2 control group (data
not shown) and the fAβ experimental group, which showed the more important overproduction of free radicals and the lowest membrane
ﬂuidity, coincide with the highest cholesterol content. However, in spite of its ability to scavenge free radicals and restore membrane ﬂuidity,
melatonin was unable to reduce cholesterol content in mitochondrial membrane. Compared according to their relative values, cholesterol
and total phospholipids ratio was signiﬁcantly altered.
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Figure 10: Signiﬁcant diﬀerences between Aβ-injected brains and
H2O2-injected brains.
proposal that Aβ paves its own way by changing the quality
and distribution of lipid membranes.
Herein we report important alterations in mitochondrial
membranes following the intracerebral injection of Aβ.
There is important in this context the relationship between
n6 and n3 PUFA, particularly the relationship between
the proinﬂammatory AA with its counterparts DHA and
EPA. EPA and DHA diﬀer in their eﬀects on plasma lipid
proﬁles, gene expression, and neural membrane structure.
EPA downregulates the enzymes involved in DHA synthesis
and decreases DHA synthesis from its precursor, α-linolenic
acid [64]. We have found that Aβ increased both DHA
and AA, while the levels of EPA remained stable, but the
treatment with melatonin, which did not aﬀect the levels
of AA, was able to increase very importantly EPA. EPA has
been reported as anti-inﬂammatory upon several conditions
and diﬀerent cell types, but importantly in aging and Aβ-
induced neuroinﬂammation [65–67]. Speciﬁcally EPA is
linked to a modulatory role in microglial activity [68]. We
have reported a remarkable reduction in microglial activity
in rats intracerebrally injected with Aβ but under melatonin
treatment [4].
Even though being examined in a diﬀerent context,
there is a report where melatonin was found protective
of AA, DHA, and EPA. Arachidonic acid was protected
more eﬃciently than DHA and EPA at all the melatonin
concentrations examined when rat liver microsomes were
incubated with ascorbic acid [69], which is quite similar to
our results (Figures 6 and 7). This phenomenon is linked to
protection against lipid peroxidation, a remarkable ability of
melatonin supported by its amphoteric nature as well as its
ability to cross the blood-brain barrier (BBB) and enter into
the central nervous system [70].
Evaluated in cortical synaptosomes from gerbils, a loss
of phospholipid asymmetry induced by Aβ1−42 has been
reported [71]. This phenomenon implies the oxidative
modiﬁcation of the ﬂippase enzyme by reactive alkenals
which causes externalization of PtdSER and the subsequent
phospholipid asymmetry, which in turn causes membrane
dysfunction,Ca++ massiveinﬂux,andapoptosis.Theanionic
PtdSER also may increase the ﬁbrillization of Aβ [72]. We
found that Aβ causes a 120% increase in PtdSER levels.
However PtdSER levels in brains of animals which received
melatonin treatment decreased 5 times compared to brains
from animals without melatonin treatment.12 International Journal of Alzheimer’s Disease
5. Conclusions
TherelationshipbetweenmembranelipidswithAβ isusually
focused on how lipids may allow, facilitate, or even induce
the amyloidogenic processing of APP. This relationship is
also explored to explain how Aβ causes cellular dysfunction.
Our approach to the in vivo study of the Aβ1−42 peptide,
the predominantly neurotoxic form of Aβ, was to inject the
peptide directly into the hippocampus and then examine
the relationship with membrane lipids, in order to explain
how Aβ may penetrate the cell and then approach to
mitochondria and cause the well-known severe dysfunction
of this organelle.
The intracellular amyloid cascade is, of course, widely
studied and elegantly explained [73–75]. It is also likely that
thepathogenicallycriticalprocessofAβ oligomerizationmay
begin intraneuronally and the energy hypometabolism may
appear before the presence of senile plaques or neuroﬁbril-
lary tangles [76]. However, without discarding the previous
statements, there is evidence to consider the extracellular
Aβ as the principal source of intracellular Aβ, given the
huge amounts of Aβ in aggregates, the physical properties
of this peptide, and its ability to alter fatty acids and lipids
on membranes, either because of its pro-oxidant activity or
because of its physical interactions with lipids.
We reported how exogenous Aβ forms deposits in
the extracellular space, then presents inside the cells—
particularly through the axons causing demyelination, which
agrees with other reports [5, 6]—and, ﬁnally, how Aβ is
found inside mitochondria where it causes severe structural
damage linked to free radical overproduction and signiﬁcant
alterations in mitochondrial membrane lipids.
By using melatonin, it is possible to ameliorate the
membrane ﬂuidity without aﬀecting cholesterol content in
membranes, while it restores the balance of lipids. Impor-
tantly, melatonin reduces the negatively charged PtdSER in
membranes and, by this means, might impair the toxicity
of Aβ. Another important feature is how melatonin may
increase EPA content in membranes, restoring the EPA/AA
ratio, a phenomenon widely known by its anti-inﬂammatory
eﬀects. Melatonin restores membrane structure and func-
tionality, an eﬀect which exclusively could not be attributed
to its antioxidant capacity.
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